ResMed Inc (RMD) shareholders
Close on Nov 17, 2026Market cap $33.46BP/E 21.7Yield 1.01%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12,783,715 | 8.70% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 11,961,706 | 8.21% | 13G (passive) | Mar 31, 2026 |
| AustralianSuper Pty Ltd | 8,276,381 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Vanguard Portfolio Management | 7,886,489 | 5.41% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | – | $2.40B | +223,171 | 0.04% |
| Vanguard Capital Management LLC | 9,474,129 | – | $1.85B | +7,713 | 0.04% |
| Vanguard Portfolio Management LLC | 7,913,661 | – | $1.54B | +49,739 | 0.07% |
| State Street Corp | 6,680,735 | – | $1.30B | +37,567 | 0.04% |
| Geode Capital Management, LLC | 4,352,320 | – | $845.16M | −553 | 0.05% |
| Bank of New York Mellon Corp | 4,197,610 | – | $818.03M | −727,776 | 0.13% |
| First Trust Advisors LP | 2,278,696 | – | $444.07M | +740,871 | 0.26% |
| Invesco Ltd. | 2,063,578 | – | $402.15M | +106,964 | 0.03% |
| Morgan Stanley | 1,928,931 | – | $375.91M | −757,890 | 0.02% |
| Northern Trust Corp | 1,696,674 | – | $330.65M | −29,019 | 0.04% |
| Nordea Investment Management Ab | 1,388,008 | – | $269.57M | +354,627 | 0.22% |
| Deutsche Bank AG\ | 1,322,313 | – | $257.69M | −100,552 | 0.07% |
| UBS Group AG | 1,289,300 | – | $251.26M | +562,489 | 0.03% |
| Swedbank AB | 1,274,897 | – | $248.45M | −75,337 | 0.21% |
| Charles Schwab Investment Management Inc | 1,222,473 | – | $238.24M | +87,174 | 0.03% |
| Goldman Sachs Group Inc | 1,160,426 | – | $226.14M | +156,221 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 1,129,739 | – | $220.16M | +679,489 | 0.10% |
| Dimensional Fund Advisors LP | 1,123,577 | – | $219.00M | +119,359 | 0.04% |
| Legal & General Group Plc | 942,614 | – | $183.70M | −47,747 | 0.04% |
| Aqr Capital Management LLC | 910,623 | – | $177.14M | +560,783 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 885 | 100M | 93 / 312 | 358 / 137 | 11M | 8M |
| Q1 2026 | 943 | 98M | 105 / 362 | 322 / 99 | 25M | 6M |
| Q4 2025 | 948 | 97M | 114 / 333 | 340 / 100 | 11M | 5M |
| Q3 2025 | 950 | 93M | 119 / 345 | 325 / 75 | 6M | 7M |
| Q2 2025 | 920 | 93M | 120 / 355 | 323 / 76 | 6M | 6M |
| Q1 2025 | 885 | 94M | 109 / 348 | 290 / 82 | 7M | 3M |
| Q4 2024 | 871 | 91M | 151 / 333 | 264 / 69 | 9M | 6M |
| Q3 2024 | 803 | 88M | 111 / 324 | 258 / 73 | 18M | 6M |
| Q2 2024 | 773 | 87M | 117 / 309 | 241 / 54 | 8M | 9M |
| Q1 2024 | 717 | 89M | 98 / 292 | 217 / 61 | 11M | 6M |
| Q4 2023 | 688 | 84M | 112 / 246 | 242 / 74 | 9M | 13M |
| Q3 2023 | 659 | 88M | 61 / 248 | 255 / 123 | 9M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
707 funds held RMD in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,605,309 | – | $897.48M | 0.04% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 3,758,092 | – | $732.38M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 3,143,005 | – | $612.51M | 0.27% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,994,871 | – | $388.76M | 0.04% | Jun 30, 2026 |
| Vanguard Growth Index Fund | 1,866,016 | – | $363.65M | 0.10% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,864,247 | – | $355.27M | 0.04% | May 31, 2026 |
| First Trust Rising Dividend Achievers ETF | 1,396,495 | – | $272.15M | 1.11% | Jun 30, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 1,111,305 | – | $216.57M | 0.62% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,024,772 | – | $199.71M | 0.49% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 963,450 | – | $203.27M | 0.21% | Jul 31, 2026 |
| Vanguard Dividend Appreciation Index Fund | 820,726 | – | $173.16M | 0.13% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 787,464 | – | $153.46M | 0.04% | Jun 30, 2026 |
| iShares U.S. Medical Devices ETF | 679,275 | – | $132.38M | 4.38% | Jun 30, 2026 |
| First Trust Capital Strength ETF | 675,234 | – | $131.59M | 1.72% | Jun 30, 2026 |
| iShares Russell Mid-Cap ETF | 597,936 | – | $116.53M | 0.20% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michael J. Farrell | Chairman and CEO, Director | 473,864 | Nov 13, 2026 |
| Aaron Bloomer | Chief Financial Officer | 7,977 | Nov 13, 2026 |
| Michael J. Rider | Global General Counsel | 10,417 | Nov 13, 2026 |
| Justin Leong | Chief Product Officer | 35,489 | Oct 1, 2026 |
| Brett Sandercock | Chief Financial Officer | 83,495 | May 4, 2026 |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | 19,430 | Aug 5, 2025 |
| Witte Jan De | Director | 4,201 | Nov 13, 2026 |
| Peter C. Farrell | Director | 1,095,808 | Nov 13, 2026 |
| Harjit Gill | Director | 10,904 | Nov 13, 2026 |
| Nicole Mowad-Nassar | Director | 777 | Nov 26, 2025 |
| Christopher DelOrefice | Director | 2,423 | Nov 24, 2025 |
| Carol Burt | Director | 18,816 | Nov 24, 2025 |
| John Hernandez | Director | 5,118 | Nov 24, 2025 |
| Desney Tan | Director | 6,002 | Nov 24, 2025 |
| Ronald R. Taylor | Director | 24,771 | Nov 24, 2025 |
| Karen Drexler | Director | 10,602 | Nov 24, 2025 |
| Richard Sulpizio | Director | 17,796 | Nov 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael J. Farrell Chairman and CEO, Director | Nov 11, 2026 | Tax withholding | −2,435.843 | $234.11 | $570.26K | 471,774 |
| Michael J. Farrell Chairman and CEO, Director | Nov 11, 2026 | Tax withholding | −2,209.793 | $234.11 | $517.33K | 474,209 |
| Michael J. Farrell Chairman and CEO, Director | Nov 11, 2026 | Tax withholding | −3,465.749 | $234.11 | $811.37K | 476,419 |
| Aaron Bloomer Chief Financial Officer | Nov 11, 2026 | Tax withholding | −1,095.137 | $234.11 | $256.38K | 7,977 |
| Peter C. Farrell Director | Nov 11, 2026 | Tax withholding | −169.142 | $234.11 | $39.60K | 51,634 |
| Michael J. Rider Global General Counsel | Nov 11, 2026 | Tax withholding | −172.993 | $234.11 | $40.50K | 10,417 |
| Michael J. Rider Global General Counsel | Nov 11, 2026 | Tax withholding | −724.414 | $234.11 | $169.59K | 10,590 |
| Michael J. Rider Global General Counsel | Nov 11, 2026 | Tax withholding | −498.624 | $234.11 | $116.73K | 11,314 |
| Michael J. Rider Global General Counsel | Nov 11, 2026 | Tax withholding | −547.469 | $234.11 | $128.17K | 11,813 |
| Witte Jan De Director | Nov 11, 2026 | Tax withholding | −59.981 | $234.11 | $14.04K | 4,201 |
| Harjit Gill Director | Nov 11, 2026 | Tax withholding | −35.731 | $234.11 | $8.36K | 10,904 |
| Michael J. Farrell Chairman and CEO, Director | Nov 9, 2026 | Sale(10b5-1 plan) | −4,993 | $235.35 | $1.18M | 479,803 |
| Michael J. Farrell Chairman and CEO, Director | Nov 9, 2026 | Option exercise | +4,310 | $146.34 | $630.73K | 484,796 |
| Michael J. Farrell Chairman and CEO, Director | Nov 9, 2026 | Option exercise | +683 | $146.34 | $99.95K | 480,486 |
| Michael J. Rider Global General Counsel | Oct 23, 2026 | Sale(10b5-1 plan) | −400 | $255.00 | $102.00K | 12,318 |
| Michael J. Farrell Chairman and CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −4,991 | $226.33 | $1.13M | 479,803 |
| Michael J. Farrell Chairman and CEO, Director | Oct 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 484,794 |
| Michael J. Farrell Chairman and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,991 | $222.44 | $1.11M | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Sep 8, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,247 |
| Peter C. Farrell Director | Sep 2, 2026 | Sale(10b5-1 plan) | −970 | $234.73 | $227.69K | 51,803 |
| Justin Leong Chief Product Officer | Aug 14, 2026 | Award | +6,461 | – | – | 35,489 |
| Michael J. Rider Global General Counsel | Aug 14, 2026 | Award | +3,230 | – | – | 12,718 |
| Michael J. Farrell Chairman and CEO, Director | Aug 14, 2026 | Award | +13,547 | – | – | 479,803 |
| Aaron Bloomer Chief Financial Officer | Aug 14, 2026 | Award | +9,072 | – | – | 9,072 |
| Michael J. Farrell Chairman and CEO, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −4,991 | $205.69 | $1.03M | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Aug 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,247 |
| Peter C. Farrell Director | Aug 5, 2026 | Sale(10b5-1 plan) | −8,000 | $225.00 | $1.80M | 52,773 |
| Michael J. Farrell Chairman and CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −4,991 | $218.55 | $1.09M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Jul 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Jun 8, 2026 | Sale(10b5-1 plan) | −4,991 | $193.96 | $968.05K | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Jun 8, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Rider Global General Counsel | Jun 1, 2026 | Tax withholding | −268.74 | $190.57 | $51.21K | 9,488 |
| Michael J. Farrell Chairman and CEO, Director | May 7, 2026 | Sale(10b5-1 plan) | −4,991 | $207.82 | $1.04M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | May 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Apr 7, 2026 | Sale(10b5-1 plan) | −4,991 | $225.50 | $1.13M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Apr 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Brett Sandercock Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −1,000 | $224.31 | $224.31K | 83,495 |
| Peter C. Farrell Director | Apr 1, 2026 | Sale(10b5-1 plan) | −2,000 | $225.00 | $450.00K | 60,773 |
| Michael J. Farrell Chairman and CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −4,991 | $251.03 | $1.25M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Mar 9, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Peter C. Farrell Director | Mar 4, 2026 | Sale(10b5-1 plan) | −2,000 | $260.22 | $520.44K | 62,773 |
| Brett Sandercock Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,000 | $254.30 | $254.30K | 84,495 |
| Michael J. Farrell Chairman and CEO, Director | Feb 9, 2026 | Sale(10b5-1 plan) | −4,991 | $273.78 | $1.37M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Feb 9, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Rider Global General Counsel | Feb 4, 2026 | Sale(10b5-1 plan) | −50 | $260.00 | $13.00K | 9,691 |
| Peter C. Farrell Director | Feb 4, 2026 | Sale(10b5-1 plan) | −2,000 | $251.31 | $502.62K | 64,773 |
| Brett Sandercock Chief Financial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −1,000 | $257.03 | $257.03K | 85,495 |
| Peter C. Farrell Director | Jan 7, 2026 | Sale(10b5-1 plan) | −2,000 | $248.83 | $497.66K | 66,773 |
| Michael J. Farrell Chairman and CEO, Director | Jan 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −4,991 | $248.46 | $1.24M | 466,223 |
| Michael J. Rider Global General Counsel | Jan 2, 2026 | Sale(10b5-1 plan) | −50 | $241.75 | $12.09K | 9,741 |
| Brett Sandercock Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −1,000 | $241.75 | $241.75K | 86,495 |
| Michael J. Farrell Chairman and CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −4,991 | $251.41 | $1.25M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Dec 8, 2025 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Peter C. Farrell Director | Dec 3, 2025 | Sale(10b5-1 plan) | −2,000 | $251.47 | $502.94K | 68,773 |
| Michael J. Rider Global General Counsel | Dec 1, 2025 | Sale(10b5-1 plan) | −50 | $244.16 | $12.21K | 9,791 |
| Brett Sandercock Chief Financial Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −1,000 | $244.16 | $244.16K | 87,495 |
| Witte Jan De Director | Nov 25, 2025 | Sale(10b5-1 plan) | −2,055 | $255.00 | $524.03K | 4,261 |
| Christopher DelOrefice Director | Nov 20, 2025 | Award | +1,073 | – | – | 2,423 |
| Ronald R. Taylor Director | Nov 20, 2025 | Award | +1,073 | – | – | 24,771 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ResMed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 84,382 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. Farrell Officer, Director | Nov 9, 2026 | 4,993 | $1.18M | Nov 9, 2026 | Stock Option Exercise |
| Michael J. Rider Officer | Oct 23, 2026 | 400 | $102.00K | Oct 23, 2026 | Restricted Stock Vesting |
| Michael J. Farrell Officer, Director | Oct 7, 2026 | 4,991 | $1.13M | Oct 7, 2026 | Stock Option Exercise |
| Michael J. Farrell Officer, Director | Sep 8, 2026 | 4,991 | $1.13M | Sep 8, 2026 | Stock Option Exercise |
| Peter C. Farrell Director | Sep 2, 2026 | 970 | $227.61K | Sep 2, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Aug 7, 2026 | 4,991 | $1.03M | Aug 7, 2026 | Stock Option Exercise |
| Peter C. Farrell Director | Aug 5, 2026 | 8,000 | $1.80M | Aug 5, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Jul 7, 2026 | 4,991 | $1.09M | Jul 7, 2026 | Stock Option Exercise |
| Michael J. Farrell Officer, Director | Jun 8, 2026 | 4,991 | $968.25K | Jun 8, 2026 | Stock Option Exercise |
| Brett Sandercock Former Officer | May 27, 2026 | 8,000 | $1.67M | May 27, 2026 | Restricted Stock Vesting |
| Michael J. Farrell Officer, Director | May 7, 2026 | 4,991 | $1.04M | May 7, 2026 | Option Granted - 11/21/2019 |
| Michael J. Farrell Officer, Director | Apr 7, 2026 | 4,991 | $1.13M | Apr 7, 2026 | Option Granted - 11/21/2019 |
| Brett Sandercock Officer | Apr 1, 2026 | 1,000 | $224.31K | Apr 1, 2026 | Restricted Stock Vesting |
| Peter C. Farrell Director | Apr 1, 2026 | 2,000 | $449.92K | Apr 1, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Mar 9, 2026 | 4,991 | $1.25M | Mar 9, 2026 | Options Granted 11/21/2019 |
Congress trades
11 trades in ResMed reported by 5 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Kelly Louise Morrison MN03 | Sold | Jun 4, 2025 | $1K–15K | Jun 18, 2025 |
| Kelly Louise Morrison MN03 | Sold | Jun 4, 2025 | $1K–15K | Jun 18, 2025 |
| Kelly Louise Morrison MN03 | Sold | Jun 4, 2025 | $1K–15K | Jun 18, 2025 |
| Kelly Louise Morrison MN03 | Sold | Jun 4, 2025 | $1K–15K | Jun 18, 2025 |
| Kelly Louise Morrison MN03 | Sold | Apr 28, 2025 | $1K–15K | May 13, 2025 |
| Rob Bresnahan PA08 · joint account | Sold | Jan 13, 2025 | $1K–15K | Feb 13, 2025 |
| Peter Meijer MI03 | Sold | Feb 16, 2021 | $1K–15K | Mar 16, 2021 |
| Susie Lee NV03 · joint account | Sold | Feb 27, 2019 | $1K–15K | Mar 12, 2019 |
| Bradley S. Schneider IL10 · spouse | Sold | Feb 5, 2019 | $250K | Feb 17, 2019 |
| Bradley S. Schneider IL10 · spouse | Bought | Mar 21, 2018 | $50K–100K | Mar 31, 2018 |
| Bradley S. Schneider IL10 · spouse | Bought | Mar 2, 2018 | $100K–250K | Mar 31, 2018 |
See a number that looks wrong?